Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
(d) Exhibits
|
Exhibit No. |
Description |
| 2.1 | Agreement and Plan of Merger and Reorganization, dated as of September12, 2017, by and among Inotek Pharmaceuticals Corporation, Rocket Pharmaceuticals, Ltd. and Rome Merger Sub (1) |
| 10.1 | Amendment to Offer Letter, effective as of September12, 2017, by and between Inotek and Rudolf A. Baumgartner, MD |
| 99.1 | Press release of Inotek Pharmaceuticals Corporation dated September12, 2017 |
| (1) | Schedules have been omitted from this filing to Item601(b)(2) of Regulation S-K. Inotek agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that Inotek may request confidential treatment to Rule 24b-2 of the Exchange Act for any schedule so furnished. |
* * *
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September13, 2017 | INOTEK PHARMACEUTICALS CORPORATION |
| By: |
/s/ Dale Ritter |
| Dale Ritter | |
| Vice President – Finance |
EXHIBIT INDEX
|
Exhibit No. |
Description |
| 2.1 | Agreement and Plan of Merger and Reorganization, dated as of September12, 2017, by and among Inotek Pharmaceuticals Corporation, Rocket Pharmaceuticals, Ltd. and Rome Merger Sub (1) |
| 10.1 | Amendment to Offer Letter, effective as of September12, 2017, by and between Inotek and Rudolf A. Baumgartner, MD |
| 99.1 | Press release of Inotek Pharmaceuticals Corporation dated September12, 2017 |
| (1) | Schedules have been omitted from this filing to Item601(b)(2) of Regulation S-K. Inotek agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that Inotek may request confidential treatment INOTEK PHARMACEUTICALS CORP ExhibitEX-2.1 2 d421363dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 CONFIDENTIAL EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: INOTEK PHARMACEUTICALS CORPORATION,…To view the full exhibit click hereAbout Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases. |
